Avalo Therapeutics (AVTX) Enterprise Value (2015 - 2026)

Avalo Therapeutics (AVTX) has 13 years of Enterprise Value data on file, last reported at -$57.2 million in Q1 2026.

• Quarterly Enterprise Value fell 92080.65% year-over-year to -$57.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$57.2 million (down 92080.65% YoY) and the FY2025 annual result came in at -$98.3 million, up 26.91% from the prior year.
• Enterprise Value grew to -$57.2 million in Q1 2026, from -$98.3 million in the prior quarter.
• In the past five years, Enterprise Value ranged from a high of -$4000.0 in Q1 2024 to a low of -$134.5 million in Q4 2024.
• A 5-year average of -$37.9 million and a median of -$13.4 million in 2023 frame the typical range for Enterprise Value.
• Annual changes were most pronounced in 2024 — Enterprise Value soared 99.98% — and 2026, when it plunged 92080.65%.
• Tracing AVTX's Enterprise Value over 5 years: stood at -$15000.0 in 2022, then slumped by 49333.33% to -$7.4 million in 2023, then slumped by 1714.51% to -$134.5 million in 2024, then rose by 26.91% to -$98.3 million in 2025, then surged by 41.88% to -$57.2 million in 2026.
• The last three Enterprise Value figures came in at -$57.2 million (Q1 2026), -$98.3 million (Q4 2025), and -$84.7 million (Q3 2025), per Business Quant data.